An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 1400 participants.
Also called NCT05667493
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,400 participants
- Registry
-
NCT05667493 -
2022-000826-74
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Poland, Portugal, Spain, Sweden, United Kingdom
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT05667493. Allocation not applicable; no masking; primary purpose treatment. Start 2022-11-30 (actual); primary completion 2029-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Condition
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
- Intervention (Drug)
- Eplontersen
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct05667493- Content hash
96d890cda173166313236a2c3ef45520545f1e43a0206947cdb8673a0e055d6f